Proton Pump Inhibitors and Preeclampsia Risk Among 157 720 Women A Swedish Population Register-Based Cohort Study

Roxanne Hastie; Lina Bergman; Catherin A Cluver; Anna Wikman; Natalie J Hannan; Susan P Walker; Anna-Karin Wikstrom; Stephen Tong; Susanne Hesselman

Journal article

Proton Pump Inhibitors and Preeclampsia Risk Among 157 720 Women A Swedish Population Register-Based Cohort Study

Roxanne Hastie, Lina Bergman, Catherin A Cluver, Anna Wikman, Natalie J Hannan, Susan P Walker, Anna-Karin Wikstrom, Stephen Tong, Susanne Hesselman

HYPERTENSION | LIPPINCOTT WILLIAMS & WILKINS | Published : 2019

DOI: 10.1161/HYPERTENSIONAHA.118.12547

University of Melbourne Researchers

A/Prof Roxanne Hastie Author

Prof Natalie Hannan Author

Prof Susan Walker Author

Prof Stephen Tong Author

Related Projects (5)

TARGETING THE TOXINS OF PREECLAMPSIA

Preeclampsia is a severe disease of pregnancy - the placenta releases toxins in to mum's bloodstream that circulate her body and damage her ..

FROM PATHOGENESIS TO THERAPEUTICS: TARGETING TWO SIGNALLING PATHWAYS AS A THERAPEUTIC STRATEGY TO TREAT PREECLAMPSIA

Preeclampsia is a serious complication of pregnancy that claims the lives of thousands of mothers and babies each year. There is no efficaci..

TRANSLATING NEW THERAPEUTICS AND DIAGNOSTICS FOR MAJOR PREGNANCY COMPLICATIONS

My research is focussed on tackling major complications of pregnancy that are a threat to the lives of both mother’s and babies. We are deve..

DEVELOPMENT OF NOVEL THERAPEUTICS TO PREVENT OR TREAT PREECLAMPSIA

Preeclampsia, a major pregnancy complication, affects ~3-8% of pregnancies. There is no cure. We have developed new strategies to tackle the..

BENCH TO BESIDE TRANSLATIONAL STUDIES TO DEVELOP TREATMENTS FOR PREECLAMPSIA

Preeclampsia is a common, devastating complication of pregnancy responsible for the loss of countless mothers and babies. There is no medica..

Grants

Awarded by National Health and Medical Research Council Fellowships

Funding Acknowledgements

R. Hastie was supported by a Melbourne Medical School, Department of Obstetrics and Gynaecology Fellowship; S. Tong (No. 1136418), F. Brownfoot (No. 1142636), and N.J. Hannan (No. 1146128) were supported by National Health and Medical Research Council Fellowships. L. Bergman and S. Hesselman were supported via a postdoc position at Center for clinical research, Falun, Sweden. The funders had no role in study design, data collection, analysis, decision to publish or the preparation of the manuscript.